Published in Hepatitis Weekly, May 10th, 2004
Valeant licensed remofovir, an orally active prodrug of the proven antiviral agent adefovir, from Metabasis in October 2001 and is primarily responsible for the clinical development of the drug.
The decision to proceed with development was based on results recently obtained from the first clinical evaluation of remofovir in patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.